Gaudium IVF, founded in 2015 operates across more than 30 locations in India, including 7 hubs and 28 spokes. They have focused on providing top support for patients along with top services to meet their needs, simultaneously, this helps to fulfill a dream of parenthood with ease and provides confidence.
Gaudium IVF and Women Health in vitro fertilization (IVF) treatment has an originality in New Delhi, one of the popular companies has filed draft papers with SEBI for an IPO, combining fresh issue and OFS, additionally, a fresh issue of Rs 1.83 crore equity shares, and an offer-for-sale of 25.31 lakh shares. Dr. Manika Khanna is a promoter of the company and sells stocks in the OFS process.
The funds raised will be utilized to help the company’s future as its expansion plans such as a new IVF Centre would be established and Investment in the company’s wholly-owned subsidiary, EKK Global Pvt Ltd, working capital needs, and the launch of FMCG products. Moreover, Sarthi Capital Advisors is selected as a lead manager for the issue.
Gaudium IVF and Women Health has a profit of Rs 16.6 crore for the fiscal year 2024, marking a 22.7% growth in contrast to the previous year. Its revenue also increased by 20.9%, reaching Rs 53.5 crore during the same period. Moreover, for the six-month period ending September 2024, the company submitted a profit of Rs 8.1 crore along with revenue of Rs 31.7 crore respectively.
Gaudium IVF, founded in 2015 operates across more than 30 locations in India, including 7 hubs and 28 spokes. They have focused on providing top support for patients along with top services to meet their needs, simultaneously, this helps to fulfill a dream of parenthood with ease and provides confidence.
Gaudium IVF and Women Health IPO Prospectus:
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | To be Updated Soon |
Gaudium IVF and Women Health Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax |
| 2022 | ₹36.52 | ₹24.52 | ₹8.83 |
| 2023 | ₹44.24 | ₹25.95 | ₹13.43 |
| 2024 | ₹53.48 | ₹30.83 | ₹16.89 |
| Sep 2024 | ₹31.69 | ₹20.78 | ₹8.28 |
Gaudium IVF and Women Health IPO Valuation – FY2024
Gaudium IVF and Women Health IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Earning Per Share (EPS): | ₹2.70 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 50% |
| Net Asset Value (NAV): | ₹335.98 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| NA | NA | NA | NA | NA | NA |
| NA | NA | NA | NA | NA | NA |
Objects of the Issue
- Funding capital expenditure towards establishment of New IVF Centers of our Company;
- Funding working capital requirements for the establishment of New IVF Centers;
- Investment in our Wholly Owned Subsidiary (WOS), EKK Global Private Limited (“EKK Global”) for; Launching of FMCG products; and Funding its Working Capital Requirements; and
- General Corporate Purposes
IPO Lead Managers aka Merchant Bankers
- Sarthi Capital Advisors Private Limited
